Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
New Isoflavone Derivatives as Potential Treatment for Cancer
Yeda R&D Co. Ltd Israel flag Israel
Abstract ID:
Improved compounds for treatment of cancer and other estrogen related diseases. Cardiovascular diseases and cancer are the leading causes of death in the U.S., accounting for almost 50% of all deaths (as of 2005). Many types of cancers are estrogen......
Contact Galit Mazooz, ph.d.
Participants
You
Email me a copy of this message

Improved compounds for treatment of cancer and other estrogen related diseases.


Cardiovascular diseases and cancer are the leading causes of death in the U.S., accounting for almost 50% of all deaths (as of 2005). Many types of cancers are estrogen sensitive (e.g. breast, colon, ovarian, prostate, etc.). Furthermore, estrogen is also related to cardiovascular health, cognitive function and other conditions. Therefore, a compound which will act as an estrogen-receptor modulator may offer a treatment to these conditions. Current modulators show success but may also cause undesirable side-effects. The present invention utilizes compounds which exhibit a potent inhibitory effect on cancer cells, and may also prevent other diseases.


Applications






    • Treatment of several cancers





    • Conjugation to a cytotoxic drug, which may facilitate its internalization to cancer cells





    • Treatment or prevention of diseases associated with the function of estrogen receptors (e.g. bone-related diseases, neurodegenerative diseases, etc.)





Advantages






    • Significant growth inhibitory effects in a variety of estrogen-sensitive cancers





    • Increased specificity and cell-penetrating properties





    • Substantial reduction of the total body exposure to the hazardous effects of the cytotoxic drug





    • Beneficial in many estrogen-related conditions





Technology's Essence


Isoflavones act as selective estrogen-receptor modulators, which are a class of medication that affects the estrogen receptor. Their action is different in various tissues, thereby granting the possibility to selectively inhibit or stimulate estrogen-like action in various tissues. The present invention relates to novel isoflavone derivatives that exhibit more potent inhibitory activity on cancer cell growth than the parent isoflavones as was shown in relevant animal models. Furthermore, the novel derivatives may be administered together with cytotoxic drugs, leading to reduced side effects.


Licensing Status

GO PREMIUM TO GET PATENT INFORMATION
FEATURED
Last Updated May 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
CORPORATION